{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:03:34Z","timestamp":1792069414779,"version":"4.4.0"},"publisher-location":"Chichester, UK","reference-count":57,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd008331.pub2","type":"reference-entry","created":{"date-parts":[[2010,6,30]],"date-time":"2010-06-30T00:47:37Z","timestamp":1277858857000},"source":"Crossref","is-referenced-by-count":22,"title":["Tocilizumab for rheumatoid arthritis"],"prefix":"10.1002","author":[{"given":"Jasvinder A","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Beg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angeles","family":"Lopez-Olivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,7]]},"reference":[{"issue":"12","key":"10.1002\/14651858.CD008331.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/art.10623","article-title":"Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. A randomized, double-blind, placebo-controlled, dose-escalation trial","volume":"46","author":"Choy","year":"2002","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD008331.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Annals of the Rheumatic Disease"},{"issue":"10","key":"10.1002\/14651858.CD008331.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","article-title":"Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis & Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD008331.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis & Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD008331.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","article-title":"Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. A multicenter, double-blind, placebo-controlled trial","volume":"50","author":"Nishimoto","year":"2004","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD008331.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab","volume":"66","author":"Nishimoto","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008331.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s10165-008-0125-1","article-title":"Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy","volume":"19","author":"Nishimoto","year":"2009","journal-title":"Modern Rheumatology"},{"key":"10.1002\/14651858.CD008331.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008331.pub2-BIB9|cit9","unstructured":"Beaulieu AD Zummer M Rubbert-Roth A Woodworth T Alecock E Alien R Targeted inhibition of the IL-6 receptor with tocilizumab effectively reduces disease activity in patients with rheumatoid arthritis Conference proceedings (ISI:000256503900089)"},{"key":"10.1002\/14651858.CD008331.pub2-BIB10|cit10","unstructured":"Hashimoto J Garnero P Miyasaka N Yamamoto K Kawai S Takeuchi T Early changes in biochemical markers of cartilage turnover and synovial inflammation predict the effects of tocilizumab monotherapy on one-year radiographic progression in patients with early rheumatoid arthritis Conference proceedings (ISI:000240877202086)"},{"key":"10.1002\/14651858.CD008331.pub2-BIB11|cit11","unstructured":"Hashimoto J Gamero P Miyasaka N Yamamoto K Kawai S Takeuchi T Humanized anti-interleukin-6 receptor antibody (tocilizumab) is effective in suppression of radiographic progression in patients with early rheumatoid arthritis, regardless of baseline levels of the predictors: Samurai study Conference proceedings (ISI:000253101100287)"},{"key":"10.1002\/14651858.CD008331.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10165-009-0170-4","article-title":"A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs","volume":"19","author":"Hashimoto","year":"2009","journal-title":"Modern Rheumatology"},{"key":"10.1002\/14651858.CD008331.pub2-BIB13|cit13","unstructured":"Kremer JM John AK Malamet R Keystone EC Evaluation of hepatic aminotransferases and bilirubin levels during tocilizumab treatment of patients with rheumatoid arthritis Conference proceedings (ISI:000266198600283)"},{"key":"10.1002\/14651858.CD008331.pub2-BIB14|cit14","first-page":"887","article-title":"Double-blind randomized controlled clinical-trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate (vol 54, pg 2817, 2006)","volume":"58","author":"Maini","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008331.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s10165-009-0159-z","article-title":"Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases","volume":"19","author":"Nagamine","year":"2009","journal-title":"Modern Rheumatology"},{"key":"10.1002\/14651858.CD008331.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3899\/jrheum.080930","article-title":"Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis","volume":"36","author":"Nakamura","year":"2009","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008331.pub2-BIB17|cit17","unstructured":"Nishimoto N Hashimoto J Miyasaka N Yamamoto K Kawai S Takeuchi T Blocking interleukin-6 (IL-6) by tocilizumab (a humanized anti-interleukin-6 receptor monoclonal antibody) monotherapy reduces joint damage in active rheumatoid arthritis (RA): evidence from a X-ray reader-blinded randomised control trial Conference proceedings (ISI:000234131500187)"},{"key":"10.1002\/14651858.CD008331.pub2-BIB18|cit18","unstructured":"Nishimoto N Miyasaka N Yamamoto K Kawai S Takeuchi T Azuma J Consistent clinical response resulted from three Japanese randomized controlled trials of tocilizumab, humanized anti-IL-6 receptor antibody, in active rheumatoid arthritis (RA) patients Conference proceedings (ISI:000240877202087)"},{"key":"10.1002\/14651858.CD008331.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008331.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2008.092866","article-title":"Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study","volume":"68","author":"NishimotoN","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008331.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2217\/14750708.5.5.663","article-title":"Efficacy of tocilizumab, a humanized anti-IL-6 receptor antibody, in rheumatoid arthritis","volume":"5","author":"Ohsugi","year":"2008","journal-title":"Therapy"},{"key":"10.1002\/14651858.CD008331.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1517\/14712598.8.5.669","article-title":"The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis","volume":"8","author":"Ohsugi","year":"2008","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1002\/14651858.CD008331.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.21826","article-title":"Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study","volume":"54","author":"Straub","year":"2006","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD008331.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD008331.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/rheumatology\/18.2.105","article-title":"Patterns of disability related to joint involvement in rheumatoid arthritis","volume":"18","author":"Badley","year":"1979","journal-title":"Rheumatology and Rehabilitation"},{"issue":"3","key":"10.1002\/14651858.CD008331.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0738-3991(98)00144-X","article-title":"Comparison of knowledge and psychological well-being between patients with a short disease duration (< or = 1 year) and patients with more established rheumatoid arthritis (> or = 10 years duration)","volume":"38","author":"Barlow","year":"1999","journal-title":"Patient Education and Counseling"},{"issue":"4","key":"10.1002\/14651858.CD008331.pub2-BIB27|cit27","first-page":"477","article-title":"Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials","volume":"170","author":"Bhandari","year":"2004","journal-title":"CMAJ"},{"issue":"3","key":"10.1002\/14651858.CD008331.pub2-BIB28|cit28","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003785","article-title":"Infliximab for the treatment of rheumatoid arthritis","author":"Blumenauer","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008331.pub2-BIB29|cit29","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004525","article-title":"Etanercept for the treatment of rheumatoid arthritis","author":"Blumenauer","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008331.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0889-857X(05)70209-X","article-title":"Rheumatoid arthritis. Treatment of early disease","volume":"27","author":"Boers","year":"2001","journal-title":"Rheumatic Diseases Clinics of North America"},{"key":"10.1002\/14651858.CD008331.pub2-BIB31|cit31","unstructured":"Cates C Visual Rx NNT Calculator version 3 [Computer program]. Dr Chris Cates' EBM website Available from http:\/\/www.nntonline.net\/visualrx\/ (accessed 13 February 2009)"},{"issue":"12","key":"10.1002\/14651858.CD008331.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/ard.2005.048975","article-title":"Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities","volume":"65","author":"Chung","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD008331.pub2-BIB33|cit33","unstructured":"Deeks J Higgins J Altman D Chapter 9: Analysing data and undertaking meta-analyses, Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008) The Cochrane Collaboration. Available from: www.cochrane-handbook.org. 2008"},{"key":"10.1002\/14651858.CD008331.pub2-BIB34|cit34","unstructured":"European Medicines Agency (EMEA) ROACTEMRA - tocilizumab. Available from: http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/RoActemra\/RoActemra.htm EMEA 2009"},{"key":"10.1002\/14651858.CD008331.pub2-BIB35|cit35","unstructured":"US Department of Health and Human Services FDA approves new drug for rheumatoid arthritis. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm197108.htm (retrieved 15 February 2010) FDA. US Food and Drug Administration"},{"issue":"6","key":"10.1002\/14651858.CD008331.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis & Rheumatism"},{"issue":"S39","key":"10.1002\/14651858.CD008331.pub2-BIB37|cit37","first-page":"S93","article-title":"The disease activity score and the EULAR response criteria","volume":"23","author":"Fransen","year":"2005","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD008331.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD008331.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/1529-0131(199904)42:3<415::AID-ANR4>3.0.CO;2-Z","article-title":"The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985","volume":"42","author":"Gabriel","year":"1999","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008331.pub2-BIB40|cit40","article-title":"Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]","volume-title":"www.cochrane-handbook.org","author":"Higgins","year":"2008"},{"issue":"5","key":"10.1002\/14651858.CD008331.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/03009740500327727","article-title":"Quality of life in rheumatoid arthritis","volume":"34","author":"Kvien","year":"2005","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD008331.pub2-BIB42|cit42","first-page":"481-91","article-title":"Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films","volume":"18","author":"Larsen","year":"1977","journal-title":"Acta Radiologic Diagnosis (Stockholm)"},{"issue":"12","key":"10.1002\/14651858.CD008331.pub2-BIB43|cit43","first-page":"1906","article-title":"Severity of disability and duration of disease in rheumatoid arthritis","volume":"19","author":"Leigh","year":"1992","journal-title":"Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD008331.pub2-BIB44|cit44","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007356","article-title":"Rituximab for rheumatoid arthritis","author":"Lopez-Olivo","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008331.pub2-BIB45|cit45","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007277","article-title":"Abatacept for rheumatoid arthritis","author":"Maxwell","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD008331.pub2-BIB46|cit46","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005121.pub3","article-title":"Anakinra for rheumatoid arthritis","author":"Mertens","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008331.pub2-BIB47|cit47","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005113.pub2","article-title":"Adalimumab for treating rheumatoid arthritis","author":"Navarro-Sarabia","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008331.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/art.1780261107","article-title":"Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire","volume":"26","author":"Pincus","year":"1983","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD008331.pub2-BIB49|cit49","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD008331.pub2-BIB50|cit50","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008"},{"issue":"15","key":"10.1002\/14651858.CD008331.pub2-BIB51|cit51","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2146\/ajhp070449","article-title":"Tocilizumab: the first interleukin-6-receptor inhibitor","volume":"65","author":"Sebba","year":"2008","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"6","key":"10.1002\/14651858.CD008331.pub2-BIB52|cit52","doi-asserted-by":"crossref","first-page":"706-20","DOI":"10.1002\/art.1780140605","article-title":"Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities","volume":"14","author":"Sharp","year":"1971","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD008331.pub2-BIB53|cit53","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008331","article-title":"Golimumab for rheumatoid arthritis","author":"Singh","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008331.pub2-BIB54|cit54","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(89)92442-2","article-title":"Effects of hydroxychloroquine and sulfasalazine on progression of joint damage in rheumatoid arthritis","volume":"1","author":"Heijde","year":"1989","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD008331.pub2-BIB55|cit55","first-page":"579","article-title":"Development of a disease activity score based on judgment in clinical practice by rheumatologists","volume":"20","author":"Heijde","year":"1993","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD008331.pub2-BIB56|cit56","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/art.1780390325","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis: comment on the article by Felson et al","volume":"39","author":"Gestel","year":"1996","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008331.pub2-BIB57|cit57","first-page":"557","article-title":"Minimum important difference between patients with rheumatoid arthritis: the patient's perspective","volume":"20","author":"Wells","year":"1993","journal-title":"Journal of Rheumatology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T08:24:10Z","timestamp":1625041450000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/14651858.CD008331.pub2"}},"subtitle":[],"editor":[{"given":"Jasvinder A","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,7,7]]},"references-count":57,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008331.pub2","relation":{},"subject":[],"published":{"date-parts":[[2010,7,7]]}}}